There is a better way to determine risk of heart disease than measuring cholesterol, according to a new study by cardiologists from the Research Institute of the McGill University Health Centre (MUHC). This study shows that measuring the amount of a protein called apoprotein B or apoB, is a more accurate and efficient test than measuring cholesterol. These findings will be published in the March issue of the international journal, The Lancet.
ôThe tradition in clinical practice is to look at the levels and ratios of cholesterol as predictors of cardiovascular disease, ö says Dr. Allan Sniderman, MUHC cardiologist and first author of the study. ôBecause this test has its limitations we decided to look at other possibilities. This study shows that apoB is a more robust indicator of a cardiac events and we suggest that it is superior to looking just at cholesterol levels.ö
Sniderman and colleagues from Australia, British Columbia, Sweden and The Netherlands, analyzed data from epidemiological studies and clinical trials involving thousands of heart patients. Their overwhelming conclusion was that, although measuring levels of cholesterol is a good start, it is not enough. ôWhen we looked at data from patients who had their cholesterol levels lowered using medications, we found that their apoB levels were still high. This suggests that these patients are still at risk of having a heart attack. This is a concern because according to the cholesterol results, the patient was adequately treated,ö says Dr. Sniderman.
Because apoproteins can be accurately and inexpensively measured in routine clinical laboratories, we suggest that this measurement should be brought into clinical practice. In addition, this test is considerably more convenient to the patients because fasting is not required, ô concludes Dr. Sniderman.
Apoproteins are specialized transport proteins that carry lipids, or fats in the blood. Most of the cholesterol in blood is present in low-density lipoprotein (LDL) particles. Each LDL particle contains one molecule of apoB, which surrounds and stabilizes it. LDL particles differ in size depending on how much cholesterol they contain. The smaller LDL particles have less cholesterol, but are associated the most with coronary artery disease and are more dangerous to have circulating in the blood than the larger LDL molecules that contain more cholesterol. An increased number of LDL particles in the blood will lead to a greater risk of heart attacks or strokes. Lowering LDL particle number is the most powerful method now available to lowering the risk of heart attacks.
For more information, please contact:
Christine Zeindler, MSc
Communications Coordinator (Research)
McGill University Health Centre Communications Services
Christine Zeindler | MUHC Communications
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
On track to heal leukaemia
18.01.2017 | Universitätsspital Bern
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy